News Ticker

[ October 8, 2026 ] From Gene Therapy to Whole-Body Health: Major ENT Research Coming to Los Angeles Los Angeles Biotech News
[ October 8, 2026 ] The Weather Company and Health Action Alliance Join Forces to Strengthen Business Preparedness Amid Weather’s Increasing Impact Los Angeles Biotech News
[ October 8, 2026 ] Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN) Los Angeles Biotech News
[ October 8, 2026 ] PreludeDx Announces the Publication of the Independent Validation of the AidaBREAST® test in npj Breast Cancer Los Angeles Biotech News
[ October 8, 2026 ] Fall Clinical 2026: Galderma Presents New Three-Year Nemluvio® Data Showing Deep and Lasting Skin Lesion and Itch Responses in Patients With Atopic Dermatitis Aged 12 and Older Los Angeles Biotech News

PreludeDx™ to Present DCISionRT® and Novel Residual Risk Subtype Study Results During Scientific Oral Session at ASBrS 2022 Annual Meeting

March 29, 2022 Los Angeles Biotechnology Network News Los Angeles Biotech News Comments Off

LAGUNA HILLS, Calif., March 29, 2022 /PRNewswire/ — Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that its study in 926 patients demonstrating the clinical utility of DCISionRT and its Residual…

Copyright © 2026 Biotech Networks, LLC